Hyperplastic polyposis syndrome and the risk of colorectal cancer: Table 1

Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer

“…The test detected also 28% to 30% of subjects with hyperplastic polyps which have traditionally not been considered as a relevant risk factor for colorectal cancer, unless present as hyperplastic polyposis syndrome (35). Whether the detection of these lesions is an added value for the test may be debatable.…”

Yield of Screening Colonoscopy in First-degree Relatives of Patients With Serrated Polyposis Syndrome

“…4,5 In an average-risk screening population the prevalence is estimated to be 1:1800, which is more frequent in occurrence than for instance familial adenomatous polyposis (1:13,000). 6,7 In contrast, with most other polyposis syndromes, the underlying genetic defect of the disease is unknown. The diagnosis of SPS is therefore based on endoscopic findings in combination with histopathology.…”

High prevalence of hyperplastic polyposis syndrome (serrated polyposis) in the NHS bowel cancer screening programme: Table 1

“…Both suggest a substantial cancer risk and continued development of serrated polyps associated with the syndrome. Previous reports have suggested that the prevalence of hyperplastic polyposis syndrome is relatively low in the general population (1:3000; 0.033%)3 with recent correspondence in Gut from Orlowska4 on this issue suggesting even lower levels (1:100 000). However, we noticed a number of cases during bowel cancer screening colonoscopy based on guaiac faecal occult blood testing (gFOBT) and, therefore, formally assessed this within our screening cohort in an audit as part of service development.…”